Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

mimedx group inc. - MDXG

MDXG

Close Chg Chg %
6.80 -0.47 -6.91%

Closed Market

6.33

-0.47 (6.91%)

Volume: 2.02M

Last Updated:

Jul 15, 2025, 4:00 PM EDT

Trade Now

Company Overview: mimedx group inc. - MDXG

MDXG Key Data

Open

$6.26

 Day Range

6.00 - 6.80

52 Week Range

5.47 - 10.14

 Market Cap

$983.70M

Shares Outstanding

147.70M

 Public Float

115.81M

Beta

1.76

 Rev. Per Employee

N/A

P/E Ratio

25.21

 EPS

$0.27

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

864.30K

  

MDXG Performance

1 Week
 
 -4.95%
 
1 Month
 
 4.80%
 
3 Months
 
 -5.24%
 
1 Year
 
 -11.59%
 
5 Years
 
 25.84%
 

MDXG Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About mimedx group inc. - MDXG

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

MDXG At a Glance

MiMedx Group, Inc.
1775 West Oak Commons Court NE
Marietta, Georgia 30062
Phone 1-770-651-9100 Revenue 348.88M
Industry Medical Specialties Net Income 42.42M
Sector Health Technology 2024 Sales Growth 8.524%
Fiscal Year-end 12 / 2025 Employees 837
View SEC Filings

MDXG Valuation

P/E Current 25.213
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 33.802
Price to Sales Ratio 4.11
Price to Book Ratio 7.32
Price to Cash Flow Ratio 21.66
Enterprise Value to EBITDA 21.719
Enterprise Value to Sales 3.882
Total Debt to Enterprise Value 0.018

MDXG Efficiency

Revenue/Employee 416,820.789
Income Per Employee 50,679.809
Receivables Turnover 6.249
Total Asset Turnover 1.387

MDXG Liquidity

Current Ratio 4.208
Quick Ratio 3.686
Cash Ratio 2.29

MDXG Profitability

Gross Margin 82.312
Operating Margin 17.00
Pretax Margin 16.422
Net Margin 12.159
Return on Assets 16.70
Return on Equity 25.012
Return on Total Capital 19.27
Return on Invested Capital 20.62

MDXG Capital Structure

Total Debt to Total Equity 12.864
Total Debt to Total Capital 11.398
Total Debt to Total Assets 9.413
Long-Term Debt to Equity 11.67
Long-Term Debt to Total Capital 10.34
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Mimedx Group Inc. - MDXG

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
258.62M 267.84M 321.48M 348.88M
Sales Growth
+4.18% +3.57% +20.03% +8.52%
Cost of Goods Sold (COGS) incl D&A
46.68M 50.55M 56.49M 61.71M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.17M 5.30M 3.43M 3.04M
Depreciation
5.35M 4.60M 2.67M 2.28M
Amortization of Intangibles
820.00K 701.00K 762.00K 765.00K
COGS Growth
+5.70% +8.28% +11.76% +9.23%
Gross Income
211.94M 217.29M 264.99M 287.17M
Gross Income Growth
+3.85% +2.53% +21.95% +8.37%
Gross Profit Margin
+81.95% +81.13% +82.43% +82.31%
2021 2022 2023 2024 5-year trend
SG&A Expense
213.13M 230.09M 222.69M 236.56M
Research & Development
17.05M 22.54M 12.36M 12.01M
Other SG&A
196.08M 207.55M 210.33M 224.54M
SGA Growth
+12.78% +7.96% -3.21% +6.23%
Other Operating Expense
3.79M 12.18M 5.18M (8.70M)
Unusual Expense
- - 53.00K 1.85M
-
EBIT after Unusual Expense
(5.04M) (24.97M) 37.12M 57.47M
Non Operating Income/Expense
(23.00K) (4.00K) (26.00K) 2.37M
Non-Operating Interest Income
- - - 2.93M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.98M 5.02M 6.46M 2.54M
Interest Expense Growth
-37.29% +0.72% +28.73% -60.69%
Gross Interest Expense
4.98M 5.02M 6.46M 2.54M
Interest Capitalized
- - - -
-
Pretax Income
(10.04M) (29.99M) 30.63M 57.29M
Pretax Income Growth
+83.69% -198.77% +202.14% +87.03%
Pretax Margin
-3.88% -11.20% +9.53% +16.42%
Income Tax
247.00K 206.00K (36.81M) 15.30M
Income Tax - Current - Domestic
- 247.00K 206.00K 2.82M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - 12.47M
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(10.29M) (30.20M) 67.44M 42.00M
Minority Interest Expense
- - - -
-
Net Income
(10.29M) (30.20M) 67.44M 42.00M
Net Income Growth
+79.13% -193.60% +323.33% -37.72%
Net Margin Growth
-3.98% -11.27% +20.98% +12.04%
Extraordinaries & Discontinued Operations
- - (9.21M) 421.00K
-
Discontinued Operations
- - (9.21M) 421.00K
-
Net Income After Extraordinaries
(10.29M) (30.20M) 58.23M 42.42M
Preferred Dividends
- 6.14M 6.58M 11.64M
Net Income Available to Common
(16.42M) (36.78M) 46.59M 42.42M
EPS (Basic)
-0.1488 -0.3257 0.3999 0.2886
EPS (Basic) Growth
+80.67% -118.88% +222.78% -27.83%
Basic Shares Outstanding
110.35M 112.91M 116.50M 146.98M
EPS (Diluted)
-0.1488 -0.3257 0.3192 0.2846
EPS (Diluted) Growth
+80.67% -118.88% +198.00% -10.84%
Diluted Shares Outstanding
110.35M 112.91M 145.96M 149.05M
EBITDA
1.19M (19.67M) 40.54M 62.35M
EBITDA Growth
+103.26% -1,752.61% +306.16% +53.80%
EBITDA Margin
+0.46% -7.34% +12.61% +17.87%

Snapshot

Average Recommendation BUY Average Target Price 12.00
Number of Ratings 5 Current Quarters Estimate 0.058
FY Report Date 09 / 2025 Current Year's Estimate 0.246
Last Quarter’s Earnings 0.05 Median PE on CY Estimate N/A
Year Ago Earnings 0.28 Next Fiscal Year Estimate 0.342
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate 0.06 0.08 0.25 0.34
High Estimates 0.07 0.09 0.28 0.40
Low Estimate 0.05 0.08 0.22 0.30
Coefficient of Variance 14.43 5.45 8.91 13.46

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 5
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Mimedx Group Inc. - MDXG

Date Name Shares Transaction Value
Apr 4, 2025 Kim Moller Chief Commercial Officer 307,316 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $7.5 per share 2,304,870.00
Mar 17, 2025 William Frank Hulse General Counsel and CAO 460,544 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.89 per share 3,633,692.16
Mar 17, 2025 William Frank Hulse General Counsel and CAO 440,178 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.89 per share 3,473,004.42
Mar 6, 2025 Joseph H. Capper Chief Executive Officer 329,530 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Joseph H. Capper Chief Executive Officer 3,777,364 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Douglas Clinton Rice Chief Financial Officer 200,773 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Douglas Clinton Rice Chief Financial Officer 201,241 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 William Frank Hulse General Counsel and CAO 108,432 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Ricci S. Whitlow Chief Operating Officer 448,948 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Ricci S. Whitlow Chief Operating Officer 107,241 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Kim Moller Chief Commercial Officer 314,942 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Kim Moller Chief Commercial Officer 75,794 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Mimedx Group Inc. in the News